A
AbCellera Biologics Inc. (ABCL)
NMS – Real Time Price. Currency in USD
7.38
+0.72 (10.81%)
At close: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
7.38
+0.72 (10.81%)
At close: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
After-hours: Jun 26, 2026, 7:58 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.05 | 6.05 | 10 | |
| Quick ratio | 13.89 | 5.63 | 10 | |
| Debt to Equity | 0.15 | 0.30 | 9.0 | |
| Debt to Assets | 0.11 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 485M | 38M | 29M | 75M | 79M |
| Gross Profit | N/A | 7M | -68M | 46M | 48M |
| Operating Income | 283M | -237M | -315M | -217M | -212M |
| Net Income | 159M | -146M | -163M | -146M | -144M |
| EBITDA | 316M | -206M | -218M | -188M | -181M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -54.06 | -20.24 | 1.0 |
| Next quarter | -14.87 | 18.8 | 5.0 |
| Current year | -57.43 | -20.41 | 1.0 |
| Next year | -3.42 | -9.23 | 1.0 |
| Weighted average score | 2.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -81.45 | -382.55 | -366.66 | 13.06 | 2.8 |
| Y/Y | 96.34 | 5.38 | 6.67 | -68.33 | 5.3 |
| 3y average | 14.75 | -64.48 | -66.29 | -68.75 | 2.8 |
| 5y average | 26.91 | -32.22 | -37.6 | 226.94 | 5.5 |
| Weighted average score | 4.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $140.2M significantly exceeds cash reserves ($102.1M), raising financial stability concerns
Total current assets $664.6M exceed Total current liabilities $47.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$37.4M limits the company's ability to reinvest or pay down debt